News
VTYX
4.090
-3.54%
-0.150
Weekly Report: what happened at VTYX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at VTYX last week (0408-0412)?
Weekly Report · 04/15 09:26
Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares
Seeking Alpha · 04/10 08:06
VENTYX BIOSCIENCES INC FILES FOR SHELF OF UP TO 11.2 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 04/09 21:09
Class Action Lawsuit against Ventyx Biosciences, Inc. (NASDAQ:VTYX)
TipRanks · 04/09 05:32
Weekly Report: what happened at VTYX last week (0401-0405)?
Weekly Report · 04/08 09:27
April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX
Barchart · 04/08 05:15
Ventyx Biosciences CBO Christopher Krueger Steps Down
TipRanks · 04/05 21:22
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Shares of Kura Sushi USA, Inc. Climbed 6% to $110.11 in pre-market trading following the release of second-quarter results. DigiAsia Corp. Shares climbed 61.8% after falling 18% on Thursday. Invivyd shares climbed 10.9% after the company issued a launch update.
Benzinga · 04/05 12:01
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact The Gross Law Firm about pending Class Action - VTYX
Shareholders of Ventyx Biosciences, Inc. Are encouraged to contact the firm regarding possible lead plaintiff appointment. The Gross Law Firm is looking for shareholders of VTYX who purchased shares of the company during the class period listed. The firm's lawsuit is on behalf of V TYX shareholders.
Barchart · 04/05 04:45
Ventyx Biosciences, Inc.: Statement of changes in beneficial ownership of securities
Press release · 04/04 01:14
Contact Levi & Korsinsky by April 30, 2024 Deadline to Join Class Action Against Ventyx Biosciences, Inc.(VTYX)
Barchart · 04/03 04:45
Ventyx Biosciences (VTYX) Gets a Buy from LifeSci Capital
TipRanks · 04/01 14:05
Weekly Report: what happened at VTYX last week (0325-0329)?
Weekly Report · 04/01 09:27
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 03/26 11:37
Weekly Report: what happened at VTYX last week (0318-0322)?
Weekly Report · 03/25 09:28
Robbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their Rights
Robbins LLP reminds investors that a shareholder filed a class action on behalf of Ventyx Biosciences, Inc. (NASDAQ: VTYX) Allegedly Misled Investors Regarding the Viability and Efficacy of its Psoriasis Drug.
Barchart · 03/18 17:02
Weekly Report: what happened at VTYX last week (0311-0315)?
Weekly Report · 03/18 09:27
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
Glancy Prongay & Murray LLP reminds investors of the upcoming April 30, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of Ventyx Biosciences, Inc. Investors. Investors who purchased stock in the Company’s October 2021 initial public offering have until April 2023 to respond to the lawsuit. The complaint alleges VentyX made false and/or misleading statements.
Barchart · 03/14 11:36
Ventyx Biosciences Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/13 14:25
More
Webull provides a variety of real-time VTYX stock news. You can receive the latest news about Ventyx Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.